Back to Authors

Xian, D.

Mayo Clinic

Bristol-Myers Squibb (United States)

Citations 1

THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)
Nowakowski, G. S., Kesanakurthy, V., Gkasiamis, Argyrios, Patah, Poliana, Delarue, Richard, Wang, T., Xian, Dehai , Martin, Peter , Morschhauser, Franck , Cartron, Guillaume , Li, J., Xian, D., Fox, Christopher P.

Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available

10.1002/hon.173_2880 Get It